Graves' Disease Pharmacotherapy in XXXX of Reproductive Age.

@entity1 @entity1375 @entity1496 @entity3937 @entity2743 @entity3028 @entity1378 @entity5652 @entity792 @entity39600
UNASSIGNED: @entity2743 is an @entity792 in which inappropriate stimulation of the thyroid gland results in unregulated secretion of thyroid hormones resulting in @entity1378 . @entity2743 is the most common cause of @entity2743 during pregnancy. Treatment options for @entity2743 include @entity39600 therapy, partial or total thyroidectomy, and radioactive @entity1496 . In this article, we review guideline recommendations for @entity2743 treatment in @entity1 of reproductive age including the recent guideline from the American College of Obstetricians and Gynecologists. Controversy regarding appropriate @entity39600 therapy before, during, and after pregnancy is reviewed. Surgical and radioactive @entity1496 therapy considerations in this @entity1 population are also reviewed. In @entity1 who may find themselves pregnant during therapy or develop @entity2743 during their pregnancy, consideration should be given to the most appropriate treatment course for the mother and fetus. @entity39600 therapy should be used with either @entity5652 or @entity3937 at appropriate doses that target the upper range of normal to slightly @entity1378 to avoid creating @entity1375 in the fetus. Consideration should also be given to the adverse effects of @entity39600 , such as @entity3028 and hepatotoxicity, with appropriate @entity1 consultation regarding signs and symptoms. Individuals who wish to breastfeed their @entity1 while taking @entity39600 should receive the lowest effective dose. Surgery should be reserved for extreme cases and limited to the second trimester, if possible. Radioactive @entity1496 therapy may be used in nonpregnant individuals, with limited harm to future fertility. Radioactive @entity1496 therapy should be withheld in pregnant @entity1 and those who are actively breastfeeding. Clinicians should keep abreast of developments in clinical trials and evidence-based recommendations regarding @entity2743 in reproductive-age @entity1 for any changes in evidence-based practice.
